Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies (2005)

  • Authors:
  • USP affiliated authors: MARANHAO, RAUL CAVALCANTE - FCF
  • USP Schools: FCF
  • DOI: 10.1007/s00280-004-0930-y
  • Subjects: NEOPLASIAS (TRATAMENTO); EMULSÕES (FORMAS FARMACÊUTICAS); LIPOPROTEÍNAS LDL
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    DOI or search this record in
    Informações sobre o DOI: 10.1007/s00280-004-0930-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Cancer Chemotherapy and Pharmacology

    ISSN: 0344-5704

    Citescore - 2017: 2.91

    SJR - 2017: 1.147

    SNIP - 2017: 0.899


  • How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      RODRIGUES, Debora Garcia; MARIA, Durvanei Augusto; FERNANDES, Denise C.; et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemotherapy and Pharmacology, Berlin, v. 55, n. 6, p. 565-576, 2005. DOI: 10.1007/s00280-004-0930-y.
    • APA

      Rodrigues, D. G., Maria, D. A., Fernandes, D. C., Valduga, C. J., Couto, R. D., Ibañez, O. C. M., & Maranhão, R. C. (2005). Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemotherapy and Pharmacology, 55( 6), 565-576. doi:10.1007/s00280-004-0930-y
    • NLM

      Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OCM, Maranhão RC. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemotherapy and Pharmacology. 2005 ; 55( 6): 565-576.
    • Vancouver

      Rodrigues DG, Maria DA, Fernandes DC, Valduga CJ, Couto RD, Ibañez OCM, Maranhão RC. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies. Cancer Chemotherapy and Pharmacology. 2005 ; 55( 6): 565-576.

    Referências citadas na obra
    Ades A, Carvalho JP, Graziani SR, Amancio RF, Souen JS, Pinotti JA, Maranhão RC (2001) Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol Oncol 82:84–87
    Constantinides PP, Lambert KJ, Tustian AK, Shneider B, Lalji S, Ma W, Wentzel B, Kesller D, Worah D, Quay SC (2000) Formulation development and antitumor activity of a filter-sterilizable emulsion of paclitaxel. Pharm Res 17(2):175–182
    Csóka K, Dhar S, Fridborg H, Larsson R, Nygren P (1997) Differential activity of cremophor EL and paclitaxel in patient tumor cells and human carcinoma cell lines in vitro. Cancer 79:1225–1233
    Entin I, Plotnikov A, Korenstein R, Keisari Y (2003) Tumor growth retardation, cure, and induction of antitumor immunity in B16 Melanoma-bearing mice by low eletric field-enhanced chemotherapy. Clin Cancer Res 9:3190–3197
    Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER (1981) Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstret Gynecol 139:877–885
    Ginsberg H, Gilbert HS, Gibson JC, Ngoc-Anh L, Virgil BW (1986) Increased low-density-lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med 96: 311–316
    Ginsburg GS, Small DM, Atkinson D (1982) Microemulsions of phospholipids and cholesterol esters. Protein-free models of low density lipoprotein. J Biol Chem 57:8216–8277
    Goble S, Bear HD (2003) Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 83(4):943–971
    Graziani SR, Igreja FAF, Hegg R, Meneghetti C, Brandizzi LI, Barboza R, Amâncio RF, Pinotti JA, Maranhão RC (2002) Uptake of a cholesterol-rich emulsion by breast cancer. Gynecol Oncol 85:493–497
    Gueddari N, Favre G, Hachem H, Marek E, Le Gaillard F, Soula G (1993) Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549. Biochemie 75:811–819
    Henriksson P, Ericsson S, Stege R, Ericsson M, Rudling M, Berglund L, Angelin B (1989) Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate. Lancet 2:1178–1180
    Hungria VTM, Latrilha MC, Rodrigues DG, Bydlowski SP, Chiattone CS, Maranhão RC (2004) Metabolism of a cholesterol-rich microemulsion (LDE) in patients with multiple myeloma and a preliminary clinical study of LDE as a drug vehicle for the treatment of the disease. Cancer Chem Pharmacol 53:51–60
    Kalechman YK, Longo DL, Catane R, Shasi A, Albeck M, Serdini B (2000) Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal transduction pathways. Int J Cancer 86:281–288
    Lundberg BB, Risovic V, Ramaswamy M, Wasan KM (2003) A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 86:93–100
    Maranhão RC, Cesar TB, Pedroso MTB, Hirata MH, Mesquita CH (1993) Metabolic behavior in rats of a nonprotein microemulsion resembling LDL. Lipids 28:691–696
    Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SMS, Coelho IJC, Meneghetti JC, Pileggi FJC, Chamone DAF (1994) Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 54:4660–4666
    Maranhão RC, Graziani SR, Yamaguchi N, Melo RF, Latrilha MC, Rodrigues DG, Couto RD, Schreier S, Buzaid AC (2002) Association of carmustine with a lipid emulsion: in vitro, in vivo and preliminary studies in cancer patients. Cancer Chem Pharmacol 49(6):487–498
    Matthews CME (1957) The theory of tracer experiments with 1331 I-labeled plasma proteins. Phys Med Biol 2:36–44
    Plowman J, Dykes DJ, Hollingshead M, Simpson H, Alley MC (1997) Human tumor xenograft models in NCI development. In: Teicher BA (ed) Anticancer drug development: preclinical screening, clinical trials and approval. Humana, Totowa, pp 101–125
    Reinecke P, Corvin J, Gabbert HE, Gerharz CD (1996) Antiproliferative effects of paclitaxel (taxol) on human renal clear cell carcinomas in vitro. Eur J Cancer 33:1122–1129
    Rodrigues DG, Covolan CC, Coradi ST, Barboza R, Maranhão RC (2002) Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. J Pharm Phamacol 56:765–772
    Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, Janoff A, Bernacki RJ (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71:103–107
    Ueyama Y, Matsuzawa U, Yamashita S, Funahashi T, Sakai N, Nakamura T, Kubo M, Tarui S (1990) Hypocholesterolemic factor from gallbladder cancer cells. Lancet 336:707–709
    Valduga CJ, Fernandes DC, Lo Prete AC, Azevedo CHM, Rodrigues DG, Maranhão RC (2003) Use of a cholesterol-rich microemulsion that binds to low-density lipoprotein receptors as vehicle for etoposide. J Pharm Pharmacol 55:1615–1622
    Verluis AJ, Rensen PC, Rump ET, Van Berkel TJ, Bijsterbosch MK (1998) Low density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br J Cancer 78(12):1607–1614
    Wang T, Wang H, Soong Y (2000) Paclitaxel-induced cell death. Cancer 88(11):2619–2628
    Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JL, VanEcho DA, VonHoff DD, Leyland J (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268